These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36891269)

  • 1. Corrigendum: Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis.
    Liu YY; Qu YY; Wang S; Luo CJ; Qiu HL; Li HT; Yuan P; Wang L; Li JL; Jiang R; Zhang R
    Front Pharmacol; 2023; 14():1155631. PubMed ID: 36891269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis.
    Liu YY; Qu YY; Wang S; Luo CJ; Qiu HL; Li HT; Yuan P; Wang L; Li JL; Jiang R; Zhang R
    Front Pharmacol; 2023; 14():1052546. PubMed ID: 36778016
    [No Abstract]   [Full Text] [Related]  

  • 3. Oral targeted therapies in the treatment of pulmonary arterial hypertension: a meta-analysis of clinical trials.
    Zheng YG; Ma H; Hu EC; Liu G; Chen G; Xiong CM
    Pulm Pharmacol Ther; 2014 Dec; 29(2):241-9. PubMed ID: 25173912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Optimization of specific therapy for pulmonary hypertension: the possibilities of riociguat].
    Martynyuk TV; Shmalts AA; Gorbachevsky SV; Chazova IE
    Ter Arkh; 2021 Sep; 93(9):1117-1124. PubMed ID: 36286873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case report: a patient with pulmonary arterial hypertension transitioning from a PDE-5 inhibitor to Riociguat.
    Poch DS
    BMC Pulm Med; 2016 May; 16(1):82. PubMed ID: 27193179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.
    Hoeper MM; Klinger JR; Benza RL; Simonneau G; Langleben D; Naeije R; Corris PA
    Respir Med; 2017 Jan; 122 Suppl 1():S18-S22. PubMed ID: 27887774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Riociguat therapy for pulmonary hypertension: a systematic review and meta-analysis.
    Wang L; Zhu L; Wu Y; Li Q; Liu H
    Ann Palliat Med; 2021 Oct; 10(10):11117-11128. PubMed ID: 34763472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corrigendum: Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model.
    Morales-Cano D; Izquierdo-García JL; Barreira B; Esquivel-Ruiz S; Callejo M; Pandolfi R; Villa-Valverde P; Rodríguez I; Cogolludo A; Ruiz-Cabello J; Perez-Vizcaino F; Moreno L
    Front Pharmacol; 2023; 14():1228923. PubMed ID: 37377931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corrigendum for efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies).
    Pulm Circ; 2023 Apr; 13(2):e12250. PubMed ID: 37362561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Riociguat for patients with chronic thromboembolic pulmonary hypertension: Usefulness of transitioning from phosphodiesterase type 5 inhibitor.
    Yamamoto K; Tanabe N; Suda R; Sasaki A; Matsumura A; Ema R; Kasai H; Kato F; Sekine A; Nishimura R; Jujo T; Sugiura T; Shigeta A; Sakao S; Tatsumi K
    Respir Investig; 2017 Jul; 55(4):270-275. PubMed ID: 28705306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of riociguat treatment on pulmonary arterial hypertension : A meta-analysis of randomized controlled trials.
    Zhao R; Jiang Y
    Herz; 2019 Nov; 44(7):637-643. PubMed ID: 29992431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The achievements of the modern specific therapy of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: focus on the stimulator of soluble guanylate cyclase riociguat].
    Gratsianskaya SE; Valieva ZS; Martynyuk TV
    Ter Arkh; 2020 Oct; 92(9):77-84. PubMed ID: 33346435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.
    Hoeper MM; Al-Hiti H; Benza RL; Chang SA; Corris PA; Gibbs JSR; Grünig E; Jansa P; Klinger JR; Langleben D; McLaughlin VV; Meyer GMB; Ota-Arakaki J; Peacock AJ; Pulido T; Rosenkranz S; Vizza CD; Vonk-Noordegraaf A; White RJ; Chang M; Kleinjung F; Meier C; Paraschin K; Ghofrani HA; Simonneau G;
    Lancet Respir Med; 2021 Jun; 9(6):573-584. PubMed ID: 33773120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of riociguat in the treatment of chronic thromboembolic pulmonary arterial hypertension: A meta-analysis.
    Ying M; Song J; Gu S; Zhao R; Li M
    Medicine (Baltimore); 2021 Jun; 100(22):e26211. PubMed ID: 34087896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of pharmacological interventions for pulmonary arterial hypertension: A network meta-analysis.
    Lin H; Wang M; Yu Y; Qin Z; Zhong X; Ma J; Zhao F; Zhang X
    Pulm Pharmacol Ther; 2018 Jun; 50():1-10. PubMed ID: 29128622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and underlying mechanism of phosphodiesterase- 5 inhibitors in preventing cognitive impairment and Alzheimer pathology: A systematic review of animal studies.
    El-Bakly W; Wagdy O; Sobhy A; Abo Elenain O; Riad MS; El Sayed M; Tarkhan S; Yassen M; Mahmoud A; Bassiony M; Nabil N
    Behav Brain Res; 2019 Oct; 372():112004. PubMed ID: 31163203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Riociguat: a review of its use in patients with chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension.
    Garnock-Jones KP
    Drugs; 2014 Nov; 74(17):2065-78. PubMed ID: 25352393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indirect treatment comparison and cost-minimization analysis of riociguat versus selexipag in patients with pulmonary arterial hypertension.
    Ornstová E; Tužil J; Chadimová K; Mlčoch T; Doležal T
    Expert Rev Pharmacoecon Outcomes Res; 2022 Dec; 22(8):1269-1275. PubMed ID: 36121156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Safety of Drugs Targeting the Nitric Oxide Pathway in Pulmonary Hypertension: A Mixed Approach Combining a Meta-Analysis of Clinical Trials and a Disproportionality Analysis From the World Health Organization Pharmacovigilance Database.
    Khouri C; Lepelley M; Roustit M; Montastruc F; Humbert M; Cracowski JL
    Chest; 2018 Jul; 154(1):136-147. PubMed ID: 29275134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modern view on the place of riociguat in the treatment of pulmonary hypertension.
    Valieva ZS; Taran IN; Martynyuk TV; Chazova IY
    Ter Arkh; 2018 Apr; 90(4):55-59. PubMed ID: 30701875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.